XRTX — XORTX Therapeutics Inc.
$0.9201-5.03%
Last close: · regular session
After-hours $0.9400 +2.16% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for XRTX in the TickerWise workspace.
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: CA
- Exchange: NASDAQ Capital Market
- Employees: 2
- Website: https://www.xortx.com
Latest SEC filings for XRTX
Latest XRTX news
- What Explains the 22% After-Hours Jump for XORTX (NASDAQ:XRTX)?
- XRTX Stock Jumps As Gout Drug Program Accelerates
- Why Did Surrozen (NASDAQ:SRZN), Zhibao Technology (NASDAQ:ZBAO), XORTX (NASDAQ:XRTX) and Vita Coco (NASDAQ:COCO) Jump?
- XORTX Therapeutics Shares Climb Over 22% After Hours
- Xortx Therapeutics Shares Rise After Company Reports Potential Partner Interest for Gout Program
- XORTX Moves to File Health Canada Trial Application for XRx-026 Gout Program
- Canadian testing is expected to speed data for XORTX (XRTX)'s planned U.S. gout drug application.
- XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.